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The effects of captopril and placebo were compared in 18 patients 
with chronic heart failure and angina pectoris with use of a 
double· blind crossover trial design. Symptoms were assessed by 
patient treatment preference, visual analogue scores and nitro· 
glycerin consumption. Exercise performance was assessed using 
two different treadmill protocols of different work intensity with 
simultaneous measurement of oxygen consumption and by supine 
bicycle exercise and simultaneous radionuclide ventriculography. 
Arrhythmias were assessed by 48 h ambulatory electrocardio· 
graphic monitoring. 
Patients generally preferred placebo to captopril, and this 
appeared to be due to an increase in symptoms of angina with 
captopril. Treadmill exercise time on a high intensity protocol was 
shorter with captopril than with placebo; on a low intensity 
Patients suffering from angina pectoris and heart failure are 
difficult to manage and have a poor prognosis. In carefully 
selected patients, coronary revascularization may be of 
benefit, but the operative morbidity and mortality rates are 
high because of poor ventricular function, age and other 
associated problems (\). Moreover, it is controversial 
whether successful revascularization can improve severely 
depressed left ventricular function (2-4). 
Medical therapy of angina and heart failure might include 
efforts to reduce preload and afterload on the left ventricle, 
induce coronary vasodilation and limit heart rate responses 
to exercise. Reduction in myocardial contractility is likely to 
be detrimental. 
Most calcium channel and beta·adrenergic receptor an-
tagonists depress cardiac function and are contraindicated in 
patients with heart failure (5,6). There is some controversial 
evidence that beta-adrenergic receptor antagonists may be of 
benefit in heart failure. but studies demonstrating success 
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protocol, angina became a more frequent limiting symptom even 
though overall exercise performance was not changed. The heart 
rate· blood pressure product was reduced, but largely because of a 
reduction in blood pressure rather than in heart rate. 
During supine bicycle exercise, no differences in symptoms, 
exercise performance, ejection fraction or changes in blood pres· 
sure were noted and ventricular arrhythmias were reduced. 
Captopril does not appear to be clinically useful in alleviating 
angina pectoris in patients with heart failure, and this effect may 
be related to a decrease in coronary perfusion pressure. Nonethe· 
less, desirable metabolic effects, a reduction in arrhythmias and 
potential effects on survival require further study of captopril in 
patients with both angina and heart failure. 
(J Am Coil CardioI1991;17:733-9) 
have started with long periods of dosing, that would be 
subtherapeutic for angina (7-9). 
Angiotensin-converting enzyme inhibitors exhibit several 
desirable properties resulting in venous and arterial dilation 
and coronary vasodilation that theoretically should be of 
benefit in angina and heart failure (10,11). Some studies 
02-16), but not others (17), have shown that these agents 
may reduce exercise-induced myocardial ischemia in pa-
tients with angina. These studies have concentrated on 
patients with angina but without evidence of heart failure. 
Patients with both heart failure and angina might be expected 
to benefit more from these agents in view of their often 
markedly elevated preload and afterload, which is largely 
due to activation of the sympathetic nervous and renin-
angiotensin systems. Studies (18-25) in animals have also 
suggested that angiotensin-converting enzyme inhibitors, 
particularly captopril, reduce myocardial damage and ar-
rhythmias during prolonged ischemia and reperfusion. A 
double-blind crossover placebo-controlled trial of captopril 
in patients with heart failure and angina pectoris is reported 
here. 
Methods 
Study patients. Four women and 14 men with heart 
failure, coronary artery disease and symptoms consistent 
with angina pectoris were studied. Their mean age was 63 ± 
6 years. All 18 had a history of one or more (range one to 
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four) myocardial infarctions confirmed by serum enzyme 
and electrocardiographic (ECG) changes and had symptoms 
consistent with Canadian Cardiovascular Society functional 
class III. No patient had had a myocardial infarction within 
3 months of the study. Three patients had anterior Q waves 
on the ECG indicative of infarction, three had inferior and 
posterior changes and five had both inferior and anterior Q 
waves; seven patients had left bundle branch block. Coro-
nary artery disease was further confirmed by angiography in 
14 patients. All patients had sinus rhythm. 
Heart failure was confirmed by physical examination, 
hemodynamic criteria and the presence of major left ventric-
ular dysfunction at rest on echocardiography and radionu-
clide ventriculography. Left ventricular end-diastolic pres-
sure was 23 ± 8 mm Hg in the 14 patients who underwent 
cardiac catheterization. The median dose of furosemide was 
120 mg/day (range 40 to 240); 10 patients were receiving 
digoxin (median dose 0.25 mg/day), 4 nitrates, 2 nifedipine 
and 2 both nifedipine and nitrates. 
The presence of reversible myocardial ischemia was 
determined on the basis of a history of typical angina 
pectoris, with pain consistently induced by exercise and 
relieved by rest. Preexisting ECG abnormalities and treat-
ment with digoxin rendered accurate interpretation of exer-
cise-induced ECG changes impossible. All patients gave 
informed written consent. The protocol was approved by the 
local ethical committee at all the institutions where patients 
were studied. 
Clinical assessment. Symptoms of breathlessness, fatigue 
and angina pectoris were assessed by visual analogue scores, 
and use of sublingual nitroglycerin was recorded in a diary. 
Patients were also asked to state their preferred treatment in 
this double-blind trial. 
Heart rate was counted from the radial pulse and blood 
pressure determined using a Hawkesly random zero sphyg-
momanometer. Weight and venous pressure were measured; 
the presence of a third heart sound was sought. 
Venous blood was taken after 30 min of supine rest and 
concentrations of electrolytes, active renin, angiotensin II 
and norepinephrine were measured. 
Exercise capacity was determined using two special 
treadmill protocols. A fast protocol was used in an attempt 
to induce maximal cardiorespiratory stress and a slow pro-
tocol to more nearly simulate the typical daily activities in 
which patients are more likely to be limited by peripheral 
factors. In the fast protocol, the treadmill speed or slope, or 
both, was changed every minute versus every 2 min in the 
slow protocol. Respiratory gas analysis was carried out 
using an Horizon Mobile Metabolic Cart (Sensormedics) to 
determine maximal oxygen consumption (26). 
Rest and exercise left ventricular ejection fraction was 
determined by multiple uptake gated acquisition and a 
multicrystal gamma camera during supine bicycle exercise 
after labeling red blood cells with technetium-99m. The 
radiation dose per evaluation was 4.8 mSv and 14.4 mSv for 
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patients completing the entire study. Exercise started at 
25 Wand was increased by 25 W every 2 min. 
Ventricular arrhythmias were monitored for 48 h in each 
phase by ambulatory ECG monitoring. A ventricular salvo 
was defined as three or more consecutive ventricular extra-
systoles and ventricular tachycardia was defined as three or 
more ventricular extrasystoles at more than 120 beats/min. 
Study design. After a 2 week period in which therapy was 
standardized and the patients were familiarized with proce-
dures, baseline assessments were carried out. Patients were 
given a test dose of 6.25 mg of captopril in an open fashion 
to ensure no severe first dose adverse reaction. If none 
occurred, patients were randomized to identical placebo or 
captopril tablets (25 mg three times daily) in a double-blind 
fashion for a 2 week period. If the patient's symptoms 
remained unchanged and the standing systolic blood pres-
sure was> 100 mm Hg, the dose of captopril was increased 
to 50 mg three times daily (or identical placebo) for a further 
4 weeks. Patients were then reassesed and crossed over in 
double-blind fashion to receive the alternative therapy in an 
identical manner for a further 6 weeks before final assess-
ment. No changes in medication other than in the drug under 
study were allowed. 
Statistical analysis. Order and period effects were ex-
cluded by comparing the differences between observations 
for the captopril and placebo phases using two-sample 
t tests; results for the captopril and placebo phases were 
compared by Student's t test with log transformation if 
appropriate. Where variables (such as exercise) were mea-
sured on more than one occasion, the Bonferroni correction 
was used to adjust for multiple t tests. Chi-square analysis 
was applied to test for differences in distribution of discrete 
variables. Samples for plasma active renin concentration and 
angiotensin II were analyzed after completion of the trial to 
protect the double-blind nature of the study. 
Results 
Effects of study design. Sixteen patients completed the 
study; 1 died suddenly at home. He did not report any 
increase in angina before his death; he was receiving pla-
cebo. One patient who was receiving nifedipine and nitrates 
developed a low arterial pressure (68/44 mm Hg) after the 
addition of captopril. Although he did not exhibit features of 
syncope or presyncope, he was withdrawn from the trial 
because of progressive hyponatremia, uremia, oliguria and 
weight gain. These changes resolved after stopping nifed-
ipine and his blood pressure increased to 96/72 mm Hg. No 
other side effects were noted. 
Five patients received captopril in a dose of 50 mg three 
times daily and 11 received a dose of25 mg three times daily. 
Symptomatic responses appeared unrelated to the dose of 
captopril used. The analysis excluded important effects of 
treatment order and suggested no deterioration in the pa-
tients' status with time. 
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Figure 1. Visual analogue scores for breathlessness, angina and 
tiredness in 18 patients. 
Symptoms (Fig. 1 and 2). Visual analogue scores for 
breathlessness and fatigue were unchanged, but scores for 
angina were worse with captopril than with placebo. The 
consumption of sublingual nitrates also increased with cap-
topril. Nine patients preferred placebo, four had no prefer-
ence and only three preferred captopril (p < 0.05 comparing 
captopril preference with other outcomes). 
Clinical signs. Heart rate and blood pressure at rest were 
lower with captopril than with placebo. Body weight was 
unchanged. Physical signs of heart failure at rest were not 
markedly changed. 
Biochemistry (Table 1). Plasma potassium, urea and cre-
atinine increased and plasma sodium was unchanged with 
captopril. Plasma renin concentration increased and plasma 
concentrations of angiotensin II and norepinephrine de-
creased. 
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Figure 2. Weekly nitroglycerin (G.T.N.) consumption from diary 
records of 18 patients. 
Treadmill exercise testing (Table 2). At baseline study, all 
patients stopped exercise both with symptoms of angina and 
breathlessness during the fast protocol, but only 10 of 18 
stopped with these symptoms during the slow test. Two 
patients stopped with breathlessness and six stopped with 
fatigue during the latter protocol. 
After statistical correction for mUltiple exercise tests, 
exercise duration was unaltered by the slow protocol, but 13 
patients became limited by angina during the captopril phase 
compared with 6 during the placebo phase (p < 0.05). 
Exercise performance was significantly worse with captopril 
during the fast protocol and patients always stopped because 
of breathlessness and angina. Maximal exercise heart rate 
was higher during the fast than during the slow protocol but 
was unchanged by the introduction of captopril. Maximal 
Table 1. Cardiorespiratory Variables Obtained at Rest and at Peak Exercise Using Two Modes of 
Exercise in 18 Patients 
Baseline Captopril Placebo p Value 
Supine 
Rest heart rate (beats/min) 82 + 4 76 + 5 80 + 3 <0.05 
Rest systolic BP (mm Hg) 128 + 10 119 + 14 126 + II <0.01 
Rest diastolic BP (mm Hg) 77 + 8 69 + 9 77 + 7 <0.01 
Erect 
Rest heart rate (beats/min) 84 + 4 81 + 6 83 + 5 NS 
Rest systolic BP (mm Hg) 127 + 9 105 + 16 125 + 8 <0.001 
Rest diastolic BP (mm Hg) 81 + 8 67 + 10 78 + 9 <0.001 
Slow protocol 
Exercise heart rate (beats/min) 120 + 16 121 + 14 122 + 15 NS 
Exercise systolic BP (mm Hg) 136 + 23 120 + 21 141 + 20 <0.002 
Exercise rate-pressure product 16.3+5.1 14.9 + 4.1 17.2 + 4.5 <0.01 
Exercise time (min) 8.7 + 3.1 9.6 + 2.4 10.9 + 3.3 NS 
Maximal oxygen consumption (ml/kg per min) 12.5 + 2.7 12.9 + 3.1 13.6 + 2.9 NS 
Fast protocol 
Exercise heart rate (beats/min) 130 + 14 133 + 13 132 + 13 NS 
Exercise systolic BP (mm Hg) 144 + 18 123 + 16 148 + 19 <0.001 
Exercise rate-pressure product 18.7 + 4.3 16.4 + 4.0 19.5+4.1 <0.01 
Exercise time (s) 234 + 22 213 + 18 255 + 24 <0.01 
Maximal oxygen consumption' (ml/kg per min) 15.4 + 3.6 14.9 + 3.0 15.7 + 3.1 NS 
'Maximal oxygen consumption achieved was consistently higher (p < 0.05) on the fast than on the slow protocol. 
BP = blood pressure. 
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Table 2. Radionuclide Ventriculography at Rest and During Supine Bicycle Exercise in 18 Patients 
Baseline 
Rest EF (%) 24 ± 8 
Exercise heart rate (beats/min) 118 + 19 
Exercise systolic BP (mm Hg) 137 + 19 
Exercise rate-pressure product 16.2 + 3.7 
Exercise EF (%) 19 ± 5 
Exercise time (s) 221 + 36 
BP = blood pressure; EF = ejection fraction. 
systolic blood pressure was similar during fast and slow 
protocols but was consistently lower during therapy with 
captopril. Recordings of diastolic blood pressure were also 
generally lower with captopril, but these noninvasive esti-
mates were considered technically unreliable and are not 
recorded here. 
Respiratory gas analysis. Maximal oxygen consumption 
was consistently greater with the shorter fast protocol. 
Maximal oxygen consumption did not vary between placebo 
and captopril phases. 
Radionuclide ventriculography (Table 3). Left ventricular 
ejection fraction decreased during exercise consistent with 
myocardial ischemia. Rest and exercise ejection fraction was 
unaltered by captopril, as was the exercise-induced change 
in ejection fraction. There was a statistically insignificant 
trend to improved exercise performance during captopril 
therapy. During the placebo phase, 8 patients stopped with 
angina, 6 of whom also complained of breathlessness, and 6 
stopped with leg fatigue; during the captopril phase, JO 
stopped with angina, 3 of whom also complained of breath-
lessness, and 4 stopped with leg fatigue. Exercise heart rate 
was similar with captopril and placebo, but exercise systolic 
blood pressure was lower with captopril. When exercise 
Captopril Placebo p Value 
24 ± 10 25 ± 8 NS 
122 + 17 124 + 20 NS 
132 + 16 140 + 13 <0.05 
16.1 + 2.8 17.4 + 3.9 NS 
17 ± 7 17 ± 6 NS 
257 + 28 232 + 24 NS 
tests during captopril and placebo therapy were compared, 
there was a significant difference between the change in 
exercise performance when supine bicycle exercise (+ II % 
in favor of captopril) and either upright treadmill protocol 
was used (-12% and -17%; p < 0.05). The reduction in 
peak exercise systolic blood pressure on captopril was also 
less marked in the supine position (p < 0.05). 
Ambulatory ECG monitoring (Table 4). The frequency of 
isolated ventricular extrasystoles and salvos was reduced, 
but the decline in ventricular tachycardia was not statisti-
cally significant with captopril versus placebo. 
Comparison of patients by clinical preference. Patients 
receiving concomitant therapy with nifedipine (n = 3) all 
preferred placebo and had more severe angina with capto-
pril. The combination of nitrates and captopril (n = 5) did not 
produce the same deleterious effects. Those patients who 
had a large decrease in systolic blood pressure with captopril 
also fared worse. Among the nine patients who had a stated 
preference for placebo, the diastolic arterial pressure at rest 
decreased by a mean of 23% with captopril, whereas it 
decreased by only 4% in three who preferred captopril. 
Baseline plasma active renin concentration tended to be 
Table 3. Plasma Urea, Creatinine, Electrolytes and Neuroendocrine Measurements at Rest 
in 16 Patients 
Baseline Captopril Placebo p Value 
Sodium (mmolliiter) 137 + 5 136 + 3 136 + 3 NS 
Potassium (mmolliiter) 3.5 + 0.6 4.0 + 0.4 3.4 + 0.7 <0.01 
Urea (mmolliiter) 7.7 + 3.6 8.9 + 5.4 7.4 + 4.0 <0.05 
Creatinine (/Lmolliiter) 113 + 24 121 + 19 112 + 18 NS 
Plasma active renin concentration 
(/LU/ml) (n = 9) 
Mean 298 2.118 214 
Median 144 2.294 112 
Range 5-1.040 14-5.234 5-720 <0.001 
Plasma angiotensin II 
(pmo1/liter) (n = 9) 
Mean 118 21 89 
Median 70 17 42 
Range 12-308 2-29 10-288 <0.001 
Plasma norepinephrine 
(nmoIl1iter) (n = 9) 
Mean 6.4 4.4 6.5 
Median 6.1 3.9 5.9 
Range 2.5-13.4 1.4-8.9 1.9-12.7 <0.05 
JACC Vol. 17, No.3 
March L 1991:733-9 
CLELAND ET AL. 737 
CAPTOPRIL AND ANGINA 
Table 4. Frequency of Ventricular Arrhythmias on 48 h Ambulatory Electrocardiographic 
Monitoring in 18 Patients 
Baseline 
Ventricular extrasystoles 
Mean 4,628 
Median Ll44 
Range 126-19,728 
Ventricular salvos 
Mean 24 
Median 6 
Range 0-128 
Ventricular tachycardia 
Mean 6 
Median 
Range 0-42 
higher in the former group (median value 162 versus 
10 p,U/liter), 
Among the 14 patients who had coronary angiography, 8 
had coronary stenosis in vessels supplying actively contract-
ing regions at rest (group A). Six had stenosis only in vessels 
supplying regions with severe wall motion abnormalities 
(group B). Six of eight patients in group A preferred placebo 
and two had no preference; only two of six patients in group 
B preferred placebo and one had no preference. 
Discussion 
Role of angiotensin-converting enzyme inhibitors in heart 
failure due to ischemic heart disease. This is the first study to 
examine the effects of medium- to long-term treatment with 
an angiotensin-converting enzyme inhibitor in patients with 
both angina and heart failure. Angiotensin-converting en-
zyme inhibitors are considered standard treatment for heart 
failure by many and this use is supported by the majority of 
published evidence (27-3\). However, some studies (32.33) 
have reported no improvement with angiotensin-converting 
enzyme inhibitors. Although this could have occurred by 
statistical chance, these studies have concentrated on pa-
tients with heart failure due to ischemic heart disease; the 
proportion of patients with residual reversible and possible 
"silent" ischemia is difficult to define. It is possible that 
exacerbation of ischemia prevented the beneficial effects of 
angiotensin-converting enzyme inhibitors on heart failure 
from being exhibited. Theoretically, captopril could reduce 
myocardial ischemia by effects on both myocardial oxygen 
demand and supply. 
Potential effects on myocardial oxygen demand. Captopril 
reduces heart rate at rest but has no marked effect on 
exercise heart rate (33) and is thus unlikely to alter ischemic 
threshold by this mechanism. Myocardial oxygen demand 
should decrease as preload and afterload on the failing left 
ventricle are reduced, as occurs with angiotensin-converting 
enzyme inhibitors both at rest and during exercise (34). 
Chatterjee et al. (35) showed that at least at rest, myocardial 
lactate production could be reversed and myocardial oxygen 
Captopril Placebo p Value 
3.478 5,088 
686 1,424 
0-13.084 342-16,024 <0.05 
14 28 
6 
0-102 0-164 <0.05 
4 
0 0 
0-24 0-32 NS 
requirements reduced in patients with left ventricular failure 
due to ischemic heart disease. Mulligan et al. (36) confirmed 
these findings and demonstrated that although coronary 
blood flow was reduced during upright bicycle exercise, 
myocardial oxygen consumption was reduced to a greater 
extent. 
Under experimental conditions, angiotensin II has posi-
tive inotropic effects (37.38), though it is not clear if these are 
sustained. This potential negative inotropic effect of capto-
pril was not manifest in this study either as a deterioration in 
heart failure or improvement in angina pectoris. Sympathetic 
activity and specifically transmyocardial norepinephrine re-
lease are reduced during exercise by angiotensin-converting 
enzyme inhibitors (36.39), and this effect has been cited as a 
potential antianginal mechanism for these agents. Plasma 
levels of norepinephrine decreased in this study, suggesting 
a reduction in sympathetic activity, though samples were 
only taken at rest. 
Potential effects on myocardial oxygen supply. Angioten-
sin-converting enzyme inhibitors dilate coronary arteries 
(40-45) but reduce arterial and coronary perfusion pressure, 
leaving coronary blood flow little changed. Angiotensin II, 
antidiuretic hormone and increased sympathetic activity 
may all contribute to increased coronary artery tone in heart 
failure (46-48). Captopril suppresses angiotensin II both at 
rest and during exercise, although antidiuretic hormone and 
plasma norepinephrine appear only significantly reduced at 
rest (28). However, although angiotensin II is a coronary 
vasoconstrictor, the constrictor effect on small distal vessels 
may undergo tachyphylaxis, whereas that on large conduc-
tance vessels is sustained (49). A reduction in angiotensin II 
could have led to large coronary vessel dilation but had little 
effect on small vessels and coronary collateral flow. Capto-
pril could also have led to an increase in focal myocardial 
ischemia by a "coronary steal" effect if distal coronary 
vasodilation did occur. 
In the present study, it is likely that a reduction in 
coronary perfusion pressure across a fixed coronary stenosis 
led to an exacerbation of angina (50). Patients whose angina 
increased with captopril had a greater decrease in blood 
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pressure. The smaller effect of angiotensin-converting en-
zyme inhibitors on coronary perfusion pressure in the supine 
position might account for the maintenance of exercise 
performance in this position. A decrease in coronary perfu-
sion pressure could also explain why patients with a stenosis 
subtending an area of relatively spared myocardium did 
worse, despite data from other studies (35,36) suggesting 
that global myocardial oxygenation is improved by angioten-
sin-converting enzyme inhibitors. 
In combination with nifedipine, significant decreases in 
blood pressure were seen, in one patient sufficient to cause 
oliguria and fluid retention. This combination was not ben-
eficial and angina increased in all three patients who could 
tolerate it. The decrease in blood pressure with the combi-
nation of nitrates and captopril was not strikingly different 
from that with captopril alone and this combination was 
generally well tolerated. 
Other effects. A decline in the number of ventricular 
extrasystoles and more complex ventricular arrhythmias 
was observed in patients treated with captopril, as has been 
previously noted. At least at rest, this benefit may have been 
due to changes in neuroendocrine activation, the increase in 
serum potassium or favorable hemodynamic changes. How-
ever, several investigators (18,21) have noted that captopril 
may have a protective effect on the myocardium during 
ischemia and reperfusion, though whether this is due to 
angiotensin-converting enzyme inhibition or ancillary prop-
erties (such as the sulphydryl group) of the molecule is 
unknown. Although captopril may not have prevented or 
even may have exacerbated exercise-induced ischemia, it 
could still have exerted a protective effect on the ischemic 
myocardium, reducing rhythm disturbances and speeding 
functional recovery (18). Putative long-term beneficial ef-
fects on myocardial function were not evident in this study, 
but it was not designed for that purpose. 
Review of other trials. Several studies have investigated 
the effects of angiotensin-converting enzyme inhibitors in 
patients with angina in the absence of heart failure, a 
situation where the renin-angiotensin system is probably not 
highly activated. Studies (13-16) reporting benefit have used 
bicycle exercise and often single doses of an angiotensin-
converting enzyme inhibitor. Studies (17) utilizing upright 
treadmill exercise and more prolonged therapy have shown 
little benefit. However, one study (13) of hypertensive 
patients with angina did suggest some benefit even during 
upright exercise. 
Present study design. Statistical analysis of this and other 
trials (28,29,32,51,52) in patients with heart failure suggest 
that the current design is appropriate at least for this 
duration of study. Heart failure is a heterogeneous condition 
and there are powerful arguments for crossover studies 
being the optimal design, as highlighted in recent discussions 
(53). 
Conclusions. Angiotensin-converting enzyme inhibitors 
continue to be a major area of interest in cardiology both 
experimentally and therapeutically. The weight of evidence 
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suggests that they are useful in relieving symptoms and 
improving functional capacity in patients with heart failure 
due to ischemic heart disease in the absence of angina. They 
may also have protective effects on the myocardium during 
ischemia and reperfusion. However, although there are 
theoretic reasons why they may prevent myocardial ische-
mia, in practice this is not the case for most patients. The 
reduction in coronary perfusion pressure during upright 
exercise may lead to the earlier onset of ischemia and 
exacerbation of angina at rest or during exercise. 
Potentially, captopril could be useful in the management 
of heart failure and angina to lessen symptoms of heart 
failure but only when other antianginal measures are taken 
that do not reduce the blood pressure excessively. The 
combination of captopril with nifedipine in patients with 
severe ventricular dysfunction, especially if blood pressure 
is already low, seems unwise. 
We thank Bristol-Myers Squibb for the supplies of captopril and matching 
placebo. 
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